Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

P. Neven, P. A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G. V. Bianchi, M. Martín, A. Nusch, G. S. Sonke, L. De la Cruz-Merino, J. T. Beck, J. P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. J. Slamon

Open source

DOI: 10.1186/s13058-023-01701-9
Published: 2023-08-31
Container: Breast Cancer Research
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s13058-023-01701-9,
  title = {Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant},
  author = {P. Neven and P. A. Fasching and S. Chia and G. Jerusalem and M. De Laurentiis and S.-A. Im and K. Petrakova and G. V. Bianchi and M. Martín and A. Nusch and G. S. Sonke and L. De la Cruz-Merino and J. T. Beck and J. P. Zarate and Y. Wang and A. Chakravartty and C. Wang and D. J. Slamon},
  year = {2023},
  journal = {Breast Cancer Research},
  doi = {10.1186/s13058-023-01701-9},
  url = {https://doi.org/10.1186/s13058-023-01701-9}
}

RIS

TY  - JOUR
TI  - Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
AU  - P. Neven
AU  - P. A. Fasching
AU  - S. Chia
AU  - G. Jerusalem
AU  - M. De Laurentiis
AU  - S.-A. Im
AU  - K. Petrakova
AU  - G. V. Bianchi
AU  - M. Martín
AU  - A. Nusch
AU  - G. S. Sonke
AU  - L. De la Cruz-Merino
AU  - J. T. Beck
AU  - J. P. Zarate
AU  - Y. Wang
AU  - A. Chakravartty
AU  - C. Wang
AU  - D. J. Slamon
PY  - 2023
JO  - Breast Cancer Research
DO  - 10.1186/s13058-023-01701-9
UR  - https://doi.org/10.1186/s13058-023-01701-9
ER  -

APA

Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., Laurentiis, M. D., Im, S., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., Cruz-Merino, L. D. L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., & Slamon, D. J. (2023). Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. Breast Cancer Research. https://doi.org/10.1186/s13058-023-01701-9

Source records

crossref · retrieved 2026-11-10T19:26:23.569Z